SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ: BSDM) is pleased to announce that Oregon Health & Science University (OHSU) has acquired a BSD-500 Hyperthermia System (BSD-500). OHSU is a leading university that provides world-class treatment for the most complex health care needs. OHSU has been ranked in U.S. News & World Report’s annual rankings as one of America’s Best Hospitals for 15 consecutive years and has been recognized in the medical specialties of cancer and endocrinology. BSD is pleased that OHSU has added the BSD-500 to its world-renowned cancer treatment program.

Oregon Health & Science University (OHSU) is one of more than 100 academic health centers in the United States. As an academic health center, OHSU offers comprehensive, cutting-edge patient care, has large research programs that explore new concepts, treatments and cures, and trains the healthcare professionals of the future. The OHSU School of Medicine faculty is recognized internationally for their pursuit of new knowledge in a breadth of investigative areas, including cancer. OHSU Healthcare provides leading-edge healthcare services to patients throughout the Pacific Northwest and beyond.

About the BSD-500 Hyperthermia System

The BSD-500 Hyperthermia System is approved by the Food and Drug Administration to deliver therapeutic heat (hyperthermia) to certain surface or subsurface malignant tumors (i.e., melanoma, squamous-or basal-cell carcinoma, adenocarcinoma, or sarcoma) by the use of either external or interstitial application of energy. The BSD-500 is used to treat patients with recurrent breast cancer. Previous studies have demonstrated that hyperthermia in conjunction with radiation significantly improved local tumor control in recurrent breast cancer patients. The data showed that previously irradiated patients, a patient group with a dismal prognosis, had the greatest increase in complete response from the addition of hyperthermia: 68.2% in the hyperthermia arm versus 23.5% in the no hyperthermia arm. There was also an indication of improved survival in the study results. (Oleson et al, “A Randomized Trial of Hyperthermia and Radiation for Superficial Tumors” (J Clin Oncol. 2005 May 1;23(13):3079-85)). As a result of this study, the National Cancer Center Network, an association comprising the 30 top tumor centers in the world, added hyperthermia treatment to its globally published guidelines on the treatment of recurrent breast cancer.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radio frequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

CONTACT:

BSD Medical Corporation, Salt Lake City
Dennis Gauger, 801-972-5555
Fax: 801-972-5930
investor@bsdmc.com

KEYWORDS:   United States  North America  Utah

INDUSTRY KEYWORDS:   Health  Hospitals  Medical Devices  Oncology  FDA  General Health

MEDIA:

Logo